Synthesis, in silico molecular docking analysis, pharmacokinetic properties and evaluation of antibacterial and antioxidant activities of fluoroquinolines

Table 1 Inhibition zone of synthesized compounds in mm (mean ± SD)

Conc. μg/L	Compounds									Ciprofloxacin	Bacterial strains
Conc. μg/L	4	5	6	7	8	9	10	15	16	Ciprofloxacin	Bacterial strains
100	11.01 ± 0.72	9.33 ± 0.33	10.50 ± 0.55	11.61 ± 0.25	11.50 ± 0.21	11.21 ± 0.11	11.01 ± 0.05	NA	NA	20.00 ± 0.76	E. coli
200	11.91 ± 0.41	10.01 ± 0.11	11.09 ± 0.57	12.21 ± 0.32	12.40 ± 0.11	11.32 ± 0.13	11.12 ± 0.07	7.01 ± 0.80	7.50 ± 0.65	22.22 ± 0.06	E. coli
100	12.20 ± 0.54	11.10 ± 0.32	9.76 ± 0.44	11.00 ± 0.72	11.70 ± 0.45	9.57 ± 0.75	8.90 ± 0.05	6.34 ± 0.01	6.54 ± 0.05	9.04 ± 0.14	P. aeruginosa
200	13.70 ± 0.98	11.80 ± 0.71	10.50 ± 0.79	11.91 ± 0.41	12.61 ± 0.52	10.40 ± 0.66	9.02 ± 0.02	7.91 ± 0.45	8.01 ± 0.55	10.05 ± 0.45	P. aeruginosa
100	11.21 ± 0.71	9.01 ± 0.64	9.31 ± 0.60	10.71 ± 0.67	13.01 ± 0.23	NA	8.88 ± 0.54	7.01 ± 0.22	7.12 ± 0.22	11.85 ± 0.91	S. aureus
200	12.01 ± 0.01	10.40 ± 0.60	9.70 ± 0.52	11.02 ± 0.56	13.60 ± 0.22	NA	9.30 ± 0.45	7.50 ± 0.81	7.81 ± 0.66	12.36 ± 0.53	S. aureus
100	13.80 ± 0.04	12.50 ± 0.43	12.90 ± 0.35	12.30 ± 0.55	14.00 ± 0.55	9.77 ± 0.33	6.61 ± 0.87	7.11 ± 0.33	7.33 ± 0.77	17.05 ± 0.67	S. pyogene
200	14.70 ± 0.04	13.00 ± 0.53	13.21 ± 0.3	12.91 ± 0.33	15.33 ± 0.33	10.21 ± 0.92	7.30 ± 0.67	7.61 ± 0.99	7.90 ± 0.11	18.20 ± 0.34	S. pyogene

Results are mean ± SD of triplicates. Ciprofloxacin was used as positive control

ISSN: 2661-801X